Author's reply to: The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

Affiliations

¹ Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
² Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
³ Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
⁴ Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.

Comment

Danielle Verver et al. Int J Cancer. 2019.

. 2019 Dec 1;145(11):3175-3176.

doi: 10.1002/ijc.32630. Epub 2019 Sep 3.

¹ Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
² Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
³ Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
⁴ Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.

No abstract available

Comment on

Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.
Verver D, van der Veldt A, van Akkooi A, Verhoef C, Grünhagen DJ, Louwman WJ. Verver D, et al. Int J Cancer. 2020 Jan 1;146(1):26-34. doi: 10.1002/ijc.32229. Epub 2019 Mar 20. Int J Cancer. 2020. PMID: 30801710 Free PMC article.
The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous.
Ellebaek E, Bastholt L, Schmidt H, Svane IM, Donia M. Ellebaek E, et al. Int J Cancer. 2019 Dec 1;145(11):3173-3174. doi: 10.1002/ijc.32631. Epub 2019 Sep 3. Int J Cancer. 2019. PMID: 31423583 No abstract available.